Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (1)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The initial no-adjustment band does not replace the separate treatment-emergent toxicity pathway.
Before applying: Review the complete toxicity table before withholding, reducing or discontinuing; severe impairment and ESRD remain outside the selected evidence.
Also check: PLUVICTO: baseline renal dosing differs from treatment-emergent toxicity
Rxlist source
GlobalRPh RX List - PLUVICTO
Product / population
Lutetium Lu 177 vipivotide tetraxetan - PLUVICTO; selected renal passages, not a complete prescribing monograph.
RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.
Renal dosing, restrictions and evidence limits
No initial adjustment is recommended at baseline Cockcroft-Gault CrCl 30-89 mL/min, but these patients may have greater toxicity risk. Monitor renal function and adverse reactions frequently. Severe impairment (15-29) and ESRD have not been studied. Baseline renal eligibility is distinct from on-treatment renal toxicity: the product has separate withholding, reduction and discontinuation rules. Hydration, frequent voiding and renal laboratory assessment before and during treatment remain necessary. Do not infer a dose for severe impairment or dialysis from the mild/moderate statement.
Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-09. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
monitoring scope
PLUVICTO: baseline renal dosing differs from treatment-emergent toxicity
The initial no-adjustment band does not replace the separate treatment-emergent toxicity pathway.
How to use this: Review the complete toxicity table before withholding, reducing or discontinuing; severe impairment and ESRD remain outside the selected evidence.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Rxlist source
GlobalRPh RX List - PLUVICTO
Lutetium Lu 177 vipivotide tetraxetan - PLUVICTO; selected renal passages, not a complete prescribing monograph.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
GlobalRPh-hosted RX List · Lutetium Lu 177 vipivotide tetraxetan - PLUVICTO; selected renal passages, not a complete prescribing monograph.
Renal method: Cockcroft-Gault creatinine clearance (CrCl), mL/min. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-09
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
No adjustment within stated limits. This does not establish dosing outside the studied renal range or population.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
No initial adjustment is recommended at baseline Cockcroft-Gault CrCl 30-89 mL/min, but these patients may have greater toxicity risk. Monitor renal function and adverse reactions frequently. Severe impairment (15-29) and ESRD have not been studied. Baseline renal eligibility is distinct from on-treatment renal toxicity: the product has separate withholding, reduction and discontinuation rules. Hydration, frequent voiding and renal laboratory assessment before and during treatment remain necessary. Do not infer a dose for severe impairment or dialysis from the mild/moderate statement.
Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.